Renaissance Technologies LLC Makes New Investment in Lumexa Imaging Holdings, Inc. $LMRI

Renaissance Technologies LLC acquired a new stake in shares of Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 90,423 shares of the company’s stock, valued at approximately $778,000. Renaissance Technologies LLC owned 0.09% of Lumexa Imaging at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of LMRI. Assetmark Inc. purchased a new stake in Lumexa Imaging in the 4th quarter worth $36,000. Geode Capital Management LLC purchased a new position in shares of Lumexa Imaging in the fourth quarter valued at about $1,548,000. Seven Grand Managers LLC bought a new position in shares of Lumexa Imaging in the fourth quarter worth about $11,942,000. Goldman Sachs Group Inc. bought a new position in shares of Lumexa Imaging in the fourth quarter worth about $18,870,000. Finally, TD Asset Management Inc purchased a new stake in shares of Lumexa Imaging during the fourth quarter worth about $1,264,000.

Lumexa Imaging Trading Down 1.5%

LMRI opened at $12.02 on Friday. The stock has a 50-day moving average of $10.85 and a 200 day moving average of $10.91. The company has a current ratio of 1.40, a quick ratio of 1.40 and a debt-to-equity ratio of 1.43. Lumexa Imaging Holdings, Inc. has a 12 month low of $6.45 and a 12 month high of $19.45. The firm has a market cap of $1.15 billion and a P/E ratio of -20.37.

Analyst Ratings Changes

A number of research firms recently commented on LMRI. Weiss Ratings raised Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a report on Thursday, June 25th. Barclays cut their price objective on shares of Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating for the company in a report on Wednesday, May 20th. Deutsche Bank Aktiengesellschaft set a $16.00 target price on shares of Lumexa Imaging in a report on Thursday. Finally, Wall Street Zen upgraded shares of Lumexa Imaging from a “hold” rating to a “buy” rating in a research report on Sunday. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Insider Activity at Lumexa Imaging

In related news, Director Brett Brodnax bought 35,000 shares of the company’s stock in a transaction dated Tuesday, May 19th. The stock was purchased at an average price of $7.25 per share, for a total transaction of $253,750.00. Following the acquisition, the director owned 62,027 shares in the company, valued at $449,695.75. This trade represents a 129.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.70% of the company’s stock.

About Lumexa Imaging

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).